Analyst Price Targets — ARGX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 4:52 pm | Alex Thompson | Stifel Nicolaus | $1,227.00 | $769.98 | StreetInsider | argenx SE (ARGX) PT Lowered to $1,227 at Stifel |
| January 20, 2026 11:11 am | — | Wells Fargo | $1,317.00 | $800.01 | TheFly | Argenx price target raised to $1,317 from $1,264 at Wells Fargo |
| January 8, 2026 12:53 pm | Danielle Brill | Truist Financial | $1,030.00 | $822.94 | TheFly | Argenx price target raised to $1,030 from $950 at Truist |
| January 8, 2026 12:36 pm | Sean Laaman | Morgan Stanley | $1,160.00 | $822.94 | TheFly | Argenx price target raised to $1,160 from $1,110 at Morgan Stanley |
| December 18, 2025 1:26 pm | Yatin Suneja | Guggenheim | $1,160.00 | $850.57 | TheFly | Argenx price target raised to $1,160 from $1,085 at Guggenheim |
| December 18, 2025 11:17 am | — | Needham | $1,006.00 | $862.05 | StreetInsider | argenx SE (ARGX) PT Raised to $1,006 at BofA Securities, 'remains one of our top picks for 2026' |
| December 18, 2025 10:13 am | Collen Kusy | Robert W. Baird | $858.00 | $862.05 | TheFly | Argenx downgraded to Neutral from Outperform at Baird |
| December 17, 2025 1:07 pm | — | RBC Capital | $925.00 | $863.37 | TheFly | Argenx price target raised to $925 from $860 at RBC Capital |
| December 11, 2025 12:14 pm | — | Stifel Nicolaus | $1,248.00 | $889.76 | TheFly | Argenx price target raised to $1,248 from $1,028 at Stifel |
| December 9, 2025 11:37 am | Xian Deng | UBS | $910.00 | $900.76 | TheFly | Argenx price target raised to $910 from $800 at UBS |
Latest News for ARGX
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis supports earlier use of VYVGART…
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis supports earlier use of VYVGART…
Shares of argenex SE (NASDAQ: ARGX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty-four brokerages that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and two have issued a strong buy recommendation on
SG Americas Securities LLC increased its stake in argenex SE (NASDAQ: ARGX) by 94.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,179 shares of the company's stock after purchasing an additional 1,548 shares during the period. SG Americas Securities LLC's holdings in
Allspring Global Investments Holdings LLC trimmed its position in shares of argenex SE (NASDAQ: ARGX) by 18.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 172,732 shares of the company's stock after selling 38,598 shares during the quarter. Allspring Global Investments
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ARGX.
Senate Trading
No Senate trades found for ARGX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.